摘要
目的:探讨复方斑蝥胶囊联合紫杉醇与顺铂化疗在中晚期子宫颈癌患者中的应用效果。方法:选取82例赣州市肿瘤医院2020年1月—2022年1月收治的中晚期子宫颈癌患者,按随机数字表法分为两组,各41例。对照组予以紫杉醇与顺铂化疗,观察组加用复方斑蝥胶囊治疗,持续治疗3个周期。比较两组临床疗效、肿瘤标志物水平、细胞免疫功能、中医症候积分、生存质量及不良反应。结果:观察组总有效率、疾病控制率均较对照组高(P<0.05),治疗后癌胚抗原(CEA)、糖类抗原125(CA125)、鳞状细胞癌相关抗原(SCC)及肿瘤特异性生长因子(TSGF)水平均低于对照组,差异均有统计学意义(P<0.05);观察组治疗后CD3+、CD4+、CD4+/CD8+均高于对照组,CD8+低于对照组,差异均有统计学意义(P<0.05);观察组治疗后神疲乏力、恶心呕吐、食欲减退及腰膝酸软积分均低于对照组,差异均有统计学意义(P<0.05);观察组治疗后生理、心理、社会、环境领域评分均高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率相比差异无统计学意义(P>0.05)。结论:复方斑蝥胶囊联合紫杉醇与顺铂化疗可提高中晚期子宫颈癌疾病控制效果,降低肿瘤标志物水平,改善免疫功能及生存质量,且安全性尚可。
Objective:To investigate the effect of Compound Cantharis Capsules combined with Paclitaxel and Cisplatin chemotherapy in patients with middle and advanced cervical cancer.Method:A total of 82 patients with middle and advanced cervical cancer admitted to Ganzhou Cancer Hospital from January 2020 to January 2022 were selected and divided into two groups according to the random number table,with 41 patients in each group.The control group was treated with Paclitaxel and Cisplatin,and the observation group added Compound Cantharis Capsules,treatment for 3 cycles.The clinical efficacy,tumor marker level,cellular immune function,TCM syndrome score,quality of life and adverse reactions of the two groups were compared.Result:The total effective rate and disease control rate in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),squamous cell carcinoma associated antigen(SCC)and tumor specific growth factor(TSGF)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+in the observation group were higher than those in the control group,while the level of CD8+in the observation group was lower than that in the control group,the differences were statistically significant(P<0.05).The scores of fatigue,nausea,vomiting,anorexia,waist and knee tenderness in the observation group were lower than those in the control group after treatment,the differences were statistically significant(P<0.05).After treatment,the scores of physiology,psychology,society and environment in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compound Cantharis Capsules combined with Paclitaxel and Cisplatin chemotherapy can improve the effect of disease control in middle and advanced cervical cancer,reduce the levels of tumor markers,improve immune function and quality of life,and is safe.
作者
许燕
XU Yan(Ganzhou Cancer Hospital,Jiangxi Province,Ganzhou 341000,China)
出处
《中国医学创新》
CAS
2023年第24期5-9,共5页
Medical Innovation of China
关键词
子宫颈癌
复方斑蝥胶囊
紫杉醇
顺铂
肿瘤标志物
细胞免疫功能
安全性
Cervical cancer
Compound Cantharis Capsules
Paclitaxel
Cisplatin
Tumor markers
Cellular immune function
Security
